The pharmacology of leishmaniasis.
The development of new strategies on chemotherapy of parasitic protozoan diseases is one of the most exciting research fields of recent years. World Health Organization (WHO) reports have recognized that the physiology and biochemistry of protozoan parasites and the host-parasite relation are the main targets for the design of new drugs that can be used in the future against these diseases.
Balaña-Fouce
R
R
Department of Physiology, Pharmacology and Toxicology (INTOXCAL), University of León, Spain.
Reguera
R M
RM
Cubría
J C
JC
Ordóñez
D
D
D000493:Allopurinol / Q000737:chemistry / Q000627:therapeutic use; D000666:Amphotericin B / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000981:Antiprotozoal Agents / Q000737:chemistry / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D017964:Itraconazole / Q000737:chemistry / Q000627:therapeutic use; D007654:Ketoconazole / Q000737:chemistry / Q000627:therapeutic use; D007891:Leishmania / Q000187:drug effects* / Q000378:metabolism; D007896:Leishmaniasis / Q000188:drug therapy* / Q000378:metabolism / Q000469:parasitology; D010303:Paromomycin / Q000737:chemistry / Q000627:therapeutic use; D014944:World Health Organization
D000981:Antiprotozoal Agents; D017964:Itraconazole; D010303:Paromomycin; D000493:Allopurinol; D000666:Amphotericin B; D007654:Ketoconazole